1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

ZMapp, 'modern techniques' too late to save doctor

 
• By Donna Young

The death of a doctor who was being treated for Ebola in the US with the best of what medical care has to offer, including the hard-to-obtain experimental drug ZMapp, was a stark reminder that in the very advanced stages, even the most modern techniques are not enough to save a patient's life when they reach a critical threshold, said Dr Jeff Gold, chancellor of the University of Nebraska Medical Center (UNMC) in Omaha.

The death of a doctor who was being treated for Ebola in the US with the best of what medical care has to offer, including the hard-to-obtain experimental drug ZMapp, was a stark reminder that in the very advanced stages, even the most modern techniques are not enough to save a patient's life when they reach a critical threshold, said Dr Jeff Gold, chancellor of the University of Nebraska Medical Center (UNMC) in Omaha.

Dr Martin Salia, a US national who was serving in his native Sierra Leone as a surgeon when he contracted Ebola, was not flown to the US for treatment until...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

More from Therapy Areas

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.